OPQ’s FY2021 report gives mixed review on state of drug quality
Regulatory NewsJoanne S. EglovitchAudit/FDA InspectionBiologicsBiotechnologyChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaOTCPharmaceuticalsQuality Assurance and Control